Mercado de diagnóstico de cáncer gástrico en América del Norte: tendencias de la industria y pronóstico hasta 2030

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado de diagnóstico de cáncer gástrico en América del Norte: tendencias de la industria y pronóstico hasta 2030

  • Healthcare IT
  • Published Report
  • Mar 2023
  • North America
  • 350 Páginas
  • Número de tablas: 123
  • Número de figuras: 56

North America Gastric Cancer Diagnostics Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
2024 –2030
Diagram Tamaño del mercado (año base)
MILLONES DE DÓLARES
Diagram Tamaño del mercado (año de pronóstico)
USD 843.49
Diagram Tasa de crecimiento anual compuesta (CAGR)
%
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Mercado de diagnóstico de cáncer gástrico en América del Norte, por tipo de producto (instrumentos, reactivos y consumibles, servicios), tipo de diagnóstico (prueba de confirmación, pruebas de detección de cáncer gástrico/examen físico), grupo de edad (adultos, niños y geriatría), tipo de enfermedad (adenocarcinoma intestinal o difuso, tumor carcinoide, tumor del estroma gastrointestinal (GIST), linfoma gástrico y otros), estadio (estadio 0, estadio I, estadio II, estadio III), género (masculino y femenino), tipo de muestra (sangre, tejido, orina y heces), usuarios finales (laboratorios de diagnóstico, hospitales, institutos de investigación del cáncer, clínicas especializadas en oncología y otros), canal de distribución (licitaciones directas y ventas minoristas): tendencias de la industria y pronóstico hasta 2030.

Mercado de diagnóstico de cáncer gástrico en América del Norte

Análisis y perspectivas del mercado de diagnóstico de cáncer gástrico en América del Norte

El aumento de la población geriátrica en América del Norte está impulsando el crecimiento de la industria de diagnóstico del cáncer gástrico. La prevalencia de tumores gastrointestinales y linfomas también ha impulsado la demanda de diagnósticos de cáncer gástrico. La principal limitación del mercado es la necesidad de reducir los altos precios asociados con las pruebas de diagnóstico del cáncer para que incluso los países en desarrollo puedan beneficiarse de ellas.

Mercado de diagnóstico de cáncer gástrico en América del NorteMercado de diagnóstico de cáncer gástrico en América del Norte

Un gran número de actores del mercado están ofreciendo productos de diagnóstico de cáncer gástrico con innovaciones que allanan el camino para el crecimiento del mercado de diagnóstico de cáncer gástrico en América del Norte.

Data Bridge Market Research analiza que se espera que el mercado de diagnóstico de cáncer gástrico en América del Norte alcance un valor de USD 843,49 millones para 2030, con una CAGR del 8,5 % durante el período de pronóstico. Los reactivos y consumibles representan el segmento de tipo de producto más grande en el mercado debido a la creciente demanda de kits y reactivos, y el aumento de los gastos de salud ha acelerado la demanda de dispositivos médicos inteligentes.

Métrica del informe

Detalles

Período de pronóstico

2023 a 2030

Año base

2022

Años históricos

2021 (Personalizable para 2015-2020)

Unidades cuantitativas

Ingresos en millones de USD, volúmenes en unidades, precios en USD

Segmentos cubiertos

Por tipo de producto (instrumentos, reactivos y consumibles, servicios), tipo de diagnóstico (prueba de confirmación, pruebas de detección de cáncer gástrico/examen físico), grupo de edad (adultos, niños y geriatría), tipo de enfermedad (adenocarcinoma intestinal o difuso, tumor carcinoide, tumor del estroma gastrointestinal (GIST), linfoma gástrico y otros), estadio (estadio 0, estadio I, estadio II, estadio III), género (masculino y femenino), tipo de muestra (sangre, tejido, orina y heces), usuarios finales (laboratorios de diagnóstico, hospitales, institutos de investigación del cáncer, clínicas especializadas en oncología y otros), canal de distribución (licitaciones directas y ventas minoristas)

Países cubiertos

Estados Unidos, Canadá y México

Actores del mercado cubiertos

BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Teco Diagnostics, Vela Diagnostics, Abbott, AdvaCare Pharma, MiRXES Pte Ltd., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, BIOCEPT, INC., FOUNDATION MEDICINE, INC., DiaSorin S.p.A, Paragon Genomics, Inc., QIAGEN, and among others

Market Definition

Stomach cancer is a type of cancer that starts in the stomach and spreads throughout the body. The stomach is a muscular pouch that lies immediately below the ribs in the upper part of the abdomen. The stomach takes in and holds the food we eat before breaking it down and digesting it. Stomach cancer, commonly referred to as gastric cancer, can occur in any section of the stomach. Stomach cancers develop in the major section of the stomach in most parts of the world (stomach body). Various diagnostic tests used for the diagnosis of cancer include prescreening tests, biopsy, biomarkers, imaging tests, PET/CT scans, and ultrasound among others.

Cancer is caused by uncontrolled, abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer.

North America Gastric Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

 Drivers

  • Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma

According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed around the world.

It is projected that the incidence of gastric cancer will rise, due to to aging and increasing population, lifestyle, and socioeconomic change. Striking variations in race, sociocultural norms, behaviors, and dietary trends are reflected in the burden and distribution of cancer in different regions across the globe.

Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics. Thus the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma are expected to drive the growth of the North America gastric cancer diagnostics market.

  • Rise in alcohol consumption and surge in smoking

Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone and so represents a severe public health issue that warrants further investigation.

A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.

Thus, the rise in alcohol consumption and surge in smoking is expected to drive the North America gastric cancer market growth.

Opportunity

  • Rise in adoption of automated systems

Cancer is a system and network illness. This indicates that in a cancer cell, certain network-related genes stop working properly. Complex interactions in such gene networks should be addressed in cancer treatment. Artificial intelligence (AI) algorithms, in particular, have been rapidly evolving, which is reflected in oncology's progress.

Machine learning and neural networks are becoming increasingly significant in precision oncology and system medicine. The combination of imaging data with clinical and molecular data opens up a world of possibilities. Radiogenomics, for instance, is a new field focused on multidimensional data processing. It can also benefit from AI advancements.

Thus, the increased adoption of automated systems acts as an opportunity for the growth of this market.

Restraint/Challenge

  • Lack of sufficient financial support from health insurance policies

To achieve their objectives, health systems require financial resources. Human resources, hospital care, and medications are the most expensive aspects of most healthcare systems. In most tropical countries, health care is funded through a combination of government, private (mainly out-of-pocket) spending, and international help.

Healthcare finance remains a key concern for low- and lower-middle-income countries. Many upper-middle-income countries in Latin America, Africa, and Asia have been able to establish health finance arrangements that cover large segments of their populations. These measures enable access to health care while also protecting individuals from catastrophic debt incurred as a result of that access. Finance, on the other hand, is a major obstacle to health care delivery in low-income countries (the bulk of which are in Sub-Saharan Africa).

Thus, the lack of sufficient financial support from health insurance policies acts as a restraint to market's growth.

Recent Developments

  • En octubre de 2022, General Electric Company colaboró ​​con varios institutos de investigación como los Hospitales de la Universidad de Cambridge, Sophia Genetics y anteriormente con Optellum para utilizar datos de imágenes en colaboración con inteligencia artificial. Esto ayudará a reducir el tiempo de diagnóstico de varios tipos de cáncer y ayudará a brindar atención personalizada a los pacientes. Esto ha ayudado a la empresa a ampliar sus horizontes en el diagnóstico del cáncer.
  • En marzo de 2020, Thermo Fisher Scientific Inc. anunció que adquiriría QIAGEN, una empresa holandesa de diagnóstico molecular y atención médica. Esta adquisición por parte de la empresa aumentará su cartera de productos en el mercado, lo que generará un aumento de los ingresos en el futuro.

Alcance del mercado de diagnóstico de cáncer gástrico en América del Norte

El mercado de diagnóstico de cáncer gástrico de América del Norte está segmentado en nueve segmentos notables según el tipo de producto, el tipo de diagnóstico, el grupo de edad, el tipo, la etapa, el género, la muestra, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.

TIPO DE PRODUCTO

  • Instrumentos
  • Reactivos y consumibles
  • Servicios

Según el tipo de producto, el mercado se segmenta en instrumentos, reactivos y consumibles y servicios.

TIPO DE DIAGNÓSTICO

  • Prueba confirmatoria
  • Pruebas de detección de cáncer gástrico/examen físico

Según el tipo de diagnóstico, el mercado está segmentado en pruebas de detección de cáncer gástrico/examen físico y pruebas confirmatorias.

GRUPO DE EDAD

  • Adulto
  • Pediátrico
  • Geriatría

Según el grupo de edad, el mercado se segmenta en adultos, pediátricos y geriátricos.

TIPO

  • Adenocarcinoma intestinal o difuso
  • Tumor carcinoide
  • Tumor del estroma gastrointestinal (GIST)
  • Linfoma gástrico
  • Otros

Según el tipo, el mercado está segmentado en adenocarcinoma intestinal o difuso, tumor carcinoide, tumor del estroma gastrointestinal (GIST), linfoma gástrico y otros.

ESCENARIO

  • Etapa 0
  • Etapa I
  • Estadio II
  • Estadio III

En función de la etapa, el mercado se segmenta en etapa 0, etapa I, etapa II y etapa III.

GÉNERO

  • Masculino
  • Femenino

En función del género, el mercado está segmentado en masculino y femenino.

TIPO DE MUESTRA

  • Sangre
  • Tejido
  • Orina
  • Heces

Según el tipo de muestra, el mercado se segmenta en sangre, tejido, orina y heces.

USUARIO FINAL

  • Laboratorios de diagnóstico
  • Hospitales
  • Institutos de investigación del cáncer
  • Clínicas especializadas en oncología
  • Otros

Sobre la base de los usuarios finales, el mercado está segmentado en laboratorios de diagnóstico, hospitales, institutos de investigación del cáncer, clínicas especializadas en oncología y otros.

CANAL DE DISTRIBUCIÓN

  • Licitaciones directas
  • Ventas al por menor

Sobre la base del canal de distribución, el mercado está segmentado en licitación directa y ventas minoristas.

Análisis y perspectivas regionales del mercado de diagnóstico de cáncer gástrico en América del Norte

El mercado de diagnóstico de cáncer gástrico de América del Norte está segmentado en nueve segmentos notables según el tipo de producto, el tipo de diagnóstico, el grupo de edad, el tipo de enfermedad, la etapa, el género, la muestra, el usuario final y el canal de distribución.

Los países cubiertos en este informe de mercado son Estados Unidos, Canadá y México.

Se espera que Estados Unidos domine debido al aumento del avance tecnológico en la industria de la salud.

La sección de países del informe también proporciona factores de impacto individuales en el mercado y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas norteamericanas y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, y el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.

Análisis del panorama competitivo y de la cuota de mercado de los diagnósticos de cáncer gástrico

El panorama competitivo del mercado de diagnóstico de cáncer gástrico de América del Norte proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en I+D, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las aprobaciones de productos, la amplitud y la extensión de los productos, el dominio de las aplicaciones y la curva de vida del tipo de producto. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa en el mercado de diagnóstico de cáncer gástrico de América del Norte.

Algunos de los principales actores que operan en el mercado de diagnóstico de cáncer gástrico de América del Norte son BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Teco Diagnostics, Vela Diagnostics, Abbott, AdvaCare Pharma, MiRXES Pte Ltd., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, BIOCEPT, INC., FOUNDATION MEDICINE, INC., DiaSorin SpA, Paragon Genomics, Inc., QIAGEN, entre otros.

 


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL'S MODEL

4.2 PORTER'S 5 FORCES

4.3 EPIDEMIOLOGY

4.4 BRAND ANALYSIS

4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET

4.6 INDUSTRY INSIGHTS:

5 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY

5.1 NORTH AMERICA

5.1.1 REGULATORY SCENARIO IN THE U.S

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA

6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING

6.1.3 INCREASE IN THE GERIATRIC POPULATION

6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS

6.2 RESTRAINTS

6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST

6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES

6.3 OPPORTUNITIES

6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS

6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS

6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS

6.4 CHALLENGES

6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES

6.4.2 LIMITATIONS OF RADIATION TESTS

7 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 REAGENTS & CONSUMABLES

7.2.1 KITS

7.2.1.1 DNA POLYMERASE KITS

7.2.1.2 PCR KITS

7.2.1.3 NUCLEIC ACID ISOLATION KITS

7.2.1.4 OTHERS

7.2.2 REAGENTS

7.2.2.1 ASSAYS

7.2.2.2 BUFFERS

7.2.2.3 PRIMERS

7.2.2.4 OTHERS

7.3 INSTRUMENTS

7.4 SERVICES

8 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE

8.1 OVERVIEW

8.2 CONFIRMATORY TEST

8.2.1 IMAGING TESTS

8.2.1.1 PET SCAN/CT SCAN

8.2.1.2 CT SCAN

8.2.1.3 ULTRASOUND

8.2.1.4 MRI

8.2.1.5 X-RAY

8.2.2 BIOMARKER

8.2.2.1 DNA BIOMARKER

8.2.2.2 RNA BIOMARKER

8.2.2.3 PROTEIN BIOMARKER

8.2.3 BIOPSY

8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM

9 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP

9.1 OVERVIEW

9.2 GERIATRICS

9.3 ADULT

9.4 PEDIATRIC

10 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE

10.1 OVERVIEW

10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA

10.3 CARCINOID TUMOR

10.4 GASTROINTESTINAL STROMAL TUMOR

10.5 GASTRIC LYMPHOMA

10.6 OTHERS

11 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE

11.1 OVERVIEW

11.2 STAGE I

11.2.1 STAGE IA

11.2.2 STAGE IB

11.3 STAGE II

11.3.1 STAGE IIA

11.3.2 STAGE IIB

11.4 STAGE III

11.4.1 STAGE IIIA

11.4.2 STAGE IIIB

11.4.3 STAGE IIIC

11.5 STAGE 0

12 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER

12.1 OVERVIEW

12.2 MALE

12.3 FEMALE

13 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE

13.1 OVERVIEW

13.2 STOOL

13.3 TISSUE

13.4 BLOOD

13.5 URINE

14 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DIAGNOSTIC LABORATORIES

14.4 CANCER RESEARCH INSTITUTES

14.5 ONCOLOGY SPECIALTY CLINICS

14.6 OTHERS

15 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDERS

15.3 RETAIL SALES

16 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION

16.1 NORTH AMERICA

16.1.1 U.S.

16.1.2 CANADA

16.1.3 MEXICO

17 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 F. HOFFMANN-LA ROCHE LTD

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 GENERAL ELECTRIC

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 ABBOTT

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 QIAGEN

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 MYRIAD GENETICS, INC.

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 ACON LABORATORIES, INC.

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 ADVACARE PHARMA

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 AGILENT TECHNOLOGIES, INC.

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 BIOMÉRIEUX

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BIOCEPT, INC.

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 BIOHIT OYJ

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 DIASORIN S.P.A

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 ENDOFOTONICS PTE LTD

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 FOUNDATION MEDICINE, INC.

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENTS

19.15 FUJIREBIO (AN H.U. GROUP COMPANY)

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 MIRXES PTE LTD.

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 PARAGON GENOMICS, INC.

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 TECO DIAGNOSTICS

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENT

19.19 THERMO FISHER SCIENTIFIC INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENTS

19.2 VELA DIAGNOSTICS

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

Lista de Tablas

TABLE 1 APPROVED COMPANION DIAGNOSTIC DEVICE

TABLE 2 THE BELOW-MENTIONED LIST SHOWS THE COST OF PET SCAN FOR CANCER DIAGNOSIS IN DIFFERENT REGIONS ACROSS THE GLOBE-

TABLE 3 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 NORTH AMERICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 NORTH AMERICA REAGENT AND CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 NORTH AMERICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 NORTH AMERICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 8 NORTH AMERICA INSTRUMENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 NORTH AMERICA SERVICES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 11 NORTH AMERICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 NORTH AMERICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA GERIATRICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA ADULT IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA PEDIATRIC IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA INTESTINAL OR DIFFUSE ADENOCARCINOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA CARCINOID TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA GASTROINTESTINAL STROMAL TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA GASTRIC LYMPHOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA STAGE 0 IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA MALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 NORTH AMERICA FEMALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 38 NORTH AMERICA STOOL IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 NORTH AMERICA TISSUE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 NORTH AMERICA BLOOD IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 NORTH AMERICA URINE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 43 NORTH AMERICA HOSPITALS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 NORTH AMERICA DIAGNOSTIC LABORATORIES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 NORTH AMERICA CANCER RESEARCH INSTITUTES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 NORTH AMERICA ONCOLOGY SPECIALTY CLINICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 NORTH AMERICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 49 NORTH AMERICA DIRECT TENDERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 NORTH AMERICA RETAIL SALES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 52 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 53 NORTH AMERICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 NORTH AMERICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 NORTH AMERICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 56 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 57 NORTH AMERICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 58 NORTH AMERICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 59 NORTH AMERICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 60 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 61 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 62 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 63 NORTH AMERICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 64 NORTH AMERICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 65 NORTH AMERICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 66 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 67 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 68 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 69 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 70 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 U.S. REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 72 U.S. KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 73 U.S. REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 74 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 75 U.S. CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 76 U.S. IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 77 U.S. BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 78 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 79 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 80 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 81 U.S. STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 82 U.S. STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 83 U.S. STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 84 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 85 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 86 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 87 U.S. GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 88 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 89 CANADA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 CANADA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 91 CANADA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 92 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 93 CANADA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 94 CANADA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 95 CANADA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 96 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 97 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 98 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 99 CANADA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 100 CANADA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 101 CANADA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 102 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 103 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 104 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 105 CANADA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 106 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 107 MEXICO REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 108 MEXICO KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 109 MEXICO REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 110 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 111 MEXICO CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 112 MEXICO IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 113 MEXICO BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 114 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 115 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 116 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 117 MEXICO STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 118 MEXICO STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 119 MEXICO STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 120 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 121 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 122 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 123 MEXICO GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

Lista de figuras

FIGURE 1 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: MARKET END COVERAGE GRID

FIGURE 11 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 INCREASE IN THE INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA IS EXPECTED TO DRIVE THE NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 13 REAGENTS AND CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, OF THE NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET

FIGURE 15 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022

FIGURE 16 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 17 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 18 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 19 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2022

FIGURE 20 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION)

FIGURE 21 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, CAGR (2023-2030)

FIGURE 22 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, LIFELINE CURVE

FIGURE 23 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022

FIGURE 24 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 25 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 26 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 27 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2022

FIGURE 28 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2023-2030 (USD MILLION)

FIGURE 29 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, CAGR (2023-2030)

FIGURE 30 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 31 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2022

FIGURE 32 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2023-2030 (USD MILLION)

FIGURE 33 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2023-2030)

FIGURE 34 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE

FIGURE 35 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2022

FIGURE 36 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)

FIGURE 37 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 38 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 39 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2022

FIGURE 40 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)

FIGURE 41 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2023-2030)

FIGURE 42 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 43 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 44 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 45 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 46 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 48 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 49 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 50 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 52 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 53 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 54 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 55 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)

FIGURE 56 NORTH AMERICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The North America Gastric Cancer Diagnostics Market is projected to grow at a CAGR of 8.5% during the forecast period by 2030.
The future market value of the North America Gastric Cancer Diagnostics Market is expected to reach USD 843.49 million by 2030.
The major players in the North America Gastric Cancer Diagnostics Market are BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., etc.
The countries covered in the North America Gastric Cancer Diagnostics Market are U.S., Canada, and Mexico.